Hepatitis B virus transgenic mice for the model of anti-hepatitis B virus drug study.
OBJECTIVE
To establish hepatitis B virus (HBV) transgenic mice models and to investigate if the model can be used for the evaluation of anti-HBV drugs.


METHODS
HBV transgenic mice models were produced by microinjection to analyze the integration, expression of HBV in the transgenic mice by nested PCR, southern blot, immunohistochemistry, and ELISA. Sixty mice whose HBV DNA, HBsAg were positive were divided into 6 groups randomly, in which 3 groups were given drugs: lamivudine administrated by perfusion of stomach tube (100mg x kg(-1) x day(-1) for 21 days); thymosine administrated by abdomen injection (3mg x day(-1) for 90 days); and DNA vaccine of 100 microg by muscle injection. The other 3 groups were negative control.


RESULTS
Lamivudine, thymosine and DNA vaccine made HBV DNA become negative in the serum of HBV transgenic mice. The negative ratio was highest in lamivudine treatment group. HBV DNA became positive again when lamivudine terminated.


CONCLUSIONS
Limvudine, thymosine, and DNA vaccine can inhibit HBV replication. Transgenic mice might be used as the model for anti-HBV drug screening and evaluation.
Transgenic Engineering Lab, Inrections Disease Centre of PLA, 458th Hospital of PLA, Guangzhou 510602, China.
Y
Y
Xiong
Y
Y
Jia
H
H
Wang
G
G
Liu
H
H
Ren
Z
Z
Zhuo
D
D
Zhang
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000235:genetics; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D013947:Thymosin / Q000627:therapeutic use; D019444:Vaccines, DNA / Q000627:therapeutic use
D000998:Antiviral Agents; D019444:Vaccines, DNA; D019259:Lamivudine; D013947:Thymosin